IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -177.83 Million SEK | -55.72% |
| 2022 | -114.2 Million SEK | -320.55% |
| 2021 | 51.78 Million SEK | 156.38% |
| 2020 | -91.84 Million SEK | 4.64% |
| 2019 | -96.31 Million SEK | -29.99% |
| 2018 | -74.09 Million SEK | -31.79% |
| 2017 | -56.22 Million SEK | -31.69% |
| 2016 | -42.69 Million SEK | -259.18% |
| 2015 | -11.88 Million SEK | -480.75% |
| 2014 | 3.12 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.05 Million SEK | 81.91% |
| 2024 Q3 | -31.65 Million SEK | -348.6% |
| 2024 Q1 | -39.01 Million SEK | -11.53% |
| 2023 Q2 | -44.9 Million SEK | 24.66% |
| 2023 Q4 | -34.98 Million SEK | 8.88% |
| 2023 FY | -177.83 Million SEK | -55.72% |
| 2023 Q3 | -38.39 Million SEK | 14.5% |
| 2023 Q1 | -59.6 Million SEK | -79.27% |
| 2022 Q3 | -23.99 Million SEK | 11.85% |
| 2022 Q2 | -27.21 Million SEK | 6.96% |
| 2022 Q1 | -29.25 Million SEK | -26.54% |
| 2022 FY | -114.2 Million SEK | -320.55% |
| 2022 Q4 | -33.24 Million SEK | -38.59% |
| 2021 Q2 | -26.62 Million SEK | -32.87% |
| 2021 FY | 51.78 Million SEK | 156.38% |
| 2021 Q4 | -23.11 Million SEK | -119.02% |
| 2021 Q1 | -20.04 Million SEK | -2.95% |
| 2021 Q3 | 121.56 Million SEK | 556.52% |
| 2020 Q2 | -26.15 Million SEK | -36.8% |
| 2020 Q3 | -26.91 Million SEK | -2.91% |
| 2020 Q4 | -19.46 Million SEK | 27.68% |
| 2020 FY | -91.84 Million SEK | 4.64% |
| 2020 Q1 | -19.11 Million SEK | 27.52% |
| 2019 FY | -96.31 Million SEK | -29.99% |
| 2019 Q4 | -26.37 Million SEK | -22.37% |
| 2019 Q3 | -21.55 Million SEK | 29.25% |
| 2019 Q2 | -30.46 Million SEK | -71.9% |
| 2019 Q1 | -17.72 Million SEK | 4.8% |
| 2018 Q1 | -15.85 Million SEK | -21.94% |
| 2018 FY | -74.09 Million SEK | -31.79% |
| 2018 Q4 | -18.61 Million SEK | -17.78% |
| 2018 Q2 | -23.82 Million SEK | -50.31% |
| 2018 Q3 | -15.8 Million SEK | 33.66% |
| 2017 Q1 | -11.89 Million SEK | 18.58% |
| 2017 Q2 | -10.64 Million SEK | 10.5% |
| 2017 Q3 | -20.68 Million SEK | -94.34% |
| 2017 Q4 | -12.99 Million SEK | 37.16% |
| 2017 FY | -56.22 Million SEK | -31.69% |
| 2016 Q1 | -10.96 Million SEK | 0.0% |
| 2016 FY | -42.69 Million SEK | -259.18% |
| 2016 Q3 | -10.61 Million SEK | -62.83% |
| 2016 Q2 | -6.51 Million SEK | 40.55% |
| 2016 Q4 | -14.6 Million SEK | -37.69% |
| 2015 FY | -11.88 Million SEK | -480.75% |
| 2014 FY | 3.12 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 28.46% |
| Ziccum AB (publ) | -21.41 Million SEK | -730.558% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -893.681% |
| BioArctic AB (publ) | 229.24 Million SEK | 177.575% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -40502.511% |
| Mendus AB (publ) | -101.61 Million SEK | -75.006% |
| Genovis AB (publ.) | 61.5 Million SEK | 389.169% |
| Intervacc AB (publ) | -102.85 Million SEK | -72.908% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -976.312% |
| Active Biotech AB (publ) | -45.8 Million SEK | -288.295% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1561.41% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -212.981% |
| Aptahem AB (publ) | -11.11 Million SEK | -1500.298% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 42.806% |
| Kancera AB (publ) | -64.88 Million SEK | -174.066% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -44.505% |
| Fluicell AB (publ) | -26.55 Million SEK | -569.726% |
| Saniona AB (publ) | -95.81 Million SEK | -85.616% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1366.351% |
| Biovica International AB (publ) | -124.82 Million SEK | -42.473% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -321.19% |
| AcouSort AB (publ) | -17.08 Million SEK | -940.664% |
| Xintela AB (publ) | -54.08 Million SEK | -228.826% |
| Abliva AB (publ) | -95.5 Million SEK | -86.201% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 45.598% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 3401.875% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1018.344% |
| Amniotics AB (publ) | -30.87 Million SEK | -476.09% |
| 2cureX AB (publ) | -32.51 Million SEK | -446.894% |
| CombiGene AB (publ) | -35.66 Million SEK | -398.632% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1286.335% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 61.852% |
| Camurus AB (publ) | 431.44 Million SEK | 141.22% |
| Corline Biomedical AB | -1.8 Million SEK | -9730.79% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -379.725% |
| I-Tech AB | 20.2 Million SEK | 980.26% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 78.618% |
| Cyxone AB (publ) | -22.98 Million SEK | -673.583% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -94.57% |
| Biosergen AB | -27.03 Million SEK | -557.762% |
| Cantargia AB (publ) | -280.02 Million SEK | 36.492% |
| NextCell Pharma AB | -41.95 Million SEK | -323.832% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 1.017% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -984.518% |
| Nanologica AB (publ) | -75.15 Million SEK | -136.623% |
| SynAct Pharma AB | -215.81 Million SEK | 17.595% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -303.684% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -649.206% |
| LIDDS AB (publ) | -40.2 Million SEK | -342.32% |
| Lipum AB (publ) | -37.17 Million SEK | -378.345% |
| BioInvent International AB (publ) | -330.3 Million SEK | 46.159% |
| Alzinova AB (publ) | -16.48 Million SEK | -979.12% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 28.611% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1690.925% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -56.931% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -743.199% |
| Simris Alg AB (publ) | -37.3 Million SEK | -376.716% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -17.115% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 54.186% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -62.725% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -1422.855% |